{"entity":{"id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.","summary":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06128837 by Luye Pharma Group Ltd., with 686 participants planned, started 2024-03-03 and due to reach its primary completion in 2028-06. Interventions recorded: Irinotecan hydrochloride liposome Injection, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06128837","url":"https://clinicaltrials.gov/study/NCT06128837"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["topotecan"],"companies":["luye-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06128837","phase":"3","setting":"A Multicenter, Randomized, Open-label, Parallel-design Phase 3 Study to Evaluate the Efficacy and Safety of LY01610 (Irinotecan Hydrochloride Liposome Injection) Versus Topotecan in Patients With Recurrent Small Cell Lung Cancer (SCLC)","sponsor":"Luye Pharma Group Ltd.","enrolled":686,"outcomes":[]},"route":"/trials/nct06128837/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}],"company":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/"}]}}